Charlotta Gauffin PhD is the new Chief Scientific Officer at Dicot

Press release: Uppsala, April 19, 2022. Charlotta Gauffin PhD has been hired as Chief Scientific Officer at Dicot starting July 11 with the task of leading the development of the company's potency drug. Dr. Gauffin has over 20 years of experience in drug development, of which more than 15 years in clinical development.

The Uppsala based pharmaceutical company Dicot has previously announced that it intends to broaden and strengthen the management for the next phase where focus will be on clinical studies, business development, and partnerships with international pharmaceutical companies. An important part of this is the appointment of a Chief Scientific Officer (CSO). The recruitment has been finalised and Dr. Charlotta Gauffin will be Dicot's new CSO from July 11.

Dr. Charlotta Gauffin has over 20 years of experience in drug development, from for example Biovitrum, Medivir, and Galderma. For the past 15 years, she has been responsible for clinical development and project management, as well as Program Director at Quintiles, and most recently Head of Clinical Operations at LIDDS AB.

“We are very happy that Charlotta is joining the company. Charlotta has just the right skills for the task of driving the company's drug development in the best way and in line with our business strategy. The recruitment of Charlotta is an important part of the work to strengthen Dicot's management team for the company's next phase”, says Elin Trampe, CEO of Dicot.

“Dicot is a company with high competence and a promising drug candidate in LIB-01. I am very much looking forward to driving Dicot's drug development and the task of taking LIB-01 into the clinical phase on the way to a future registration”, says Charlotta Gauffin, Dicot's new CSO.

For further information, please contact:

Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.